News
Great week for Bristol-Myers Squibb Company (NYSE:BMY) institutional investors after losing 0.8% over the previous year
1+ day, 10+ hour ago Institutions' substantial holdings in Bristol-Myers Squibb implies that they have significant influence over the company's share price A total of 24 investors have a majority stake in the company with 50% ownership Every investor in Bristol-Myers Squibb Company (NYSE:BMY) should be…...
Bristol Myers Squibb Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans
2+ day, 2+ hour ago Agreement Provides Tariff Relief for a 3-Year Period As part of the agreement, BMS will address the Administration's four priority areas: Make Eliquis available to Medicaid for free starting on January 1, 2026, lowering costs for patients and the healthcare system. Contribute…...
Bristol Myers Squibb Canada Welcomes Positive CDA Recommendation for OPDIVO® Plus YERVOY® as First-Line Treatment for MSI-H/dMMR Metastatic Colorectal Cancer
3+ day, 22+ hour ago Bristol Myers Squibb Canada (BMS) today announced that Canada's Drug Agency (CDA-AMC) has issued a positive reimbursement recommendation for OPDIVO" (nivolumab) in combination with YERVOY" (ipilimumab) for the first-line treatment of adult patients with unresectable or metastatic microsatellite instability-high (MSI-H)…...
Tariffs, shipping risks prompt Stamford-based Lovesac shift to U.S. manufacturing
6+ day, 31+ min ago Citing a double whammy of tariffs and the ongoing specter of supply disruptions - including the possibility of high-seas piracy - one of Connecticut's fastest-growing retailers is doubling down on plans to shift manufacturing to the United States. Based in Stamford, Lovesac…...
Bristol Myers Squibb Announces Dividend Increase
1+ week, 4+ day ago Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty-three cents ($0.63) per share on the $0.10 par value common stock of the company ... Oops, something went wrong Bristol Myers Squibb Announces Dividend…...
Bristol Myers Squibb Advances Lymphoma Research with New Targeted Protein Degradation and Cell Therapy Data at ASH 2025
1+ week, 6+ day ago PRINCETON, N.J., December 08, 2025--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) reinforces its hematology leadership through new research across multiple therapies for patients with lymphoma at the 67th American Society of Hematology (ASH) Annual Meeting. Two-year follow-up of golcadomide plus R-CHOP in patients…...
Bristol Myers Squibb’s Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL)
2+ week, 2+ day ago In the MZL cohort of TRANSCEND FL, Breyanzi delivered deep and durable responses in 95.5% of patients while demonstrating a consistent safety profile Breyanzi is now the only CAR T cell therapy approved by the FDA for five cancer types, the…...
BridgePort and Segal Marco Advisors Bring Digital Innovation to Private Investment Diligence and Advisory Solutions for the Wealth Channel
2+ week, 4+ day ago BridgePort, a financial technology company that provides bespoke technology and infrastructure solutions to sophisticated clients across the private markets value chain, has entered into an agreement with Segal Marco Advisors, one of the largest U.S.-based investment consultancies. The collaboration brings…...
Dispatch Bio Announces Clinical Supply and Collaboration Agreement with Bristol Myers Squibb in Solid Tumors
1+ mon, 2+ week ago PHILADELPHIA & SAN FRANCISCO, November 04, 2025--Dispatch Bio, a biotech company engineering a universal treatment across solid tumors leveraging its first-in-class Flare platform, today announced a clinical supply and collaboration agreement with Bristol Myers Squibb ("BMS") to support the development of Dispatch's…...
Bristol Myers Squibb Reports Third Quarter Financial Results for 2025
1+ mon, 3+ week ago Bristol Myers Squibb (NYSE: BMY) today reported third quarter 2025 financial results. Visit the company's Investor Relations website at to view the detailed third quarter 2025 earnings press release ... Oops, something went wrong Bristol Myers Squibb Reports Third Quarter Financial Results for…...